{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T10:29:29Z","timestamp":1697365769988},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1007\/s11938-004-0037-x","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T15:27:35Z","timestamp":1180884455000},"page":"161-167","source":"Crossref","is-referenced-by-count":4,"title":["Newer therapies for inflammatory bowel disease"],"prefix":"10.1007","volume":"7","author":[{"given":"Peter","family":"Legnani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asher","family":"Kornbluth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"37_CR1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"S Hanauer","year":"2002","unstructured":"Hanauer S, Feagan B, Lichtenstein G, et al.: Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet 2002, 359: 1541\u20131549. Important study.","journal-title":"Lancet"},{"key":"37_CR2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2036.2003.01686.x","volume":"18","author":"J Gornet","year":"2003","unstructured":"Gornet J, Couve S, Hassani Z, et al.: Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther 2003, 18: 175\u2013181.","journal-title":"Aliment Pharmacol Ther"},{"key":"37_CR3","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/gut.52.7.998","volume":"52","author":"C Probert","year":"2003","unstructured":"Probert C, Hearing S, Schreiber S, et al.: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003, 52: 998\u20131002.","journal-title":"Gut"},{"key":"37_CR4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med 2003, 348: 601\u2013608.","journal-title":"N Engl J Med"},{"key":"37_CR5","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","volume":"98","author":"A Cheifetz","year":"2003","unstructured":"Cheifetz A, Smedley M, Martin S, et al.: The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003, 98: 1315\u20131324.","journal-title":"Am J Gastroenterol"},{"key":"37_CR6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","volume":"126","author":"J Colombel","year":"2004","unstructured":"Colombel J, Loftus EJ, Tremaine W, et al.: The safety profile of infliximab in patients with Crohn\u2019s disease: The Mayo clinic experience in 500 patients. Gastroenterology 2004, 126: 19\u201331.","journal-title":"Gastroenterology"},{"key":"37_CR7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1572-0241.2003.04010.x","volume":"99","author":"G Lichtenstein","year":"2004","unstructured":"Lichtenstein G, Yan S, Bala M, Hanauer S: Remission in patients with Crohn\u2019s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004, 99: 91\u201396.","journal-title":"Am J Gastroenterol"},{"key":"37_CR8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00004836-200308000-00006","volume":"37","author":"D Prajamati","year":"2003","unstructured":"Prajamati D, Knox J, Emmons J, et al.: Leflunomide treatment of Crohn\u2019s disease patients intolerant to standard immunomodulator therapy. J Clin Gastroenterol 2003, 37: 125\u2013128.","journal-title":"J Clin Gastroenterol"},{"key":"37_CR9","doi-asserted-by":"crossref","unstructured":"Winter T, Wright J, Ghosh S, et al.: Intravenous CDP870, a humanized anti-TNF antibody fragment in patients with active Crohn\u2019s disease\u2014an exploratory study. Gastroenterology 2003:A377.","DOI":"10.1016\/S0016-5085(03)81906-6"},{"key":"37_CR10","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1111\/j.1572-0241.2001.04705.x","volume":"96","author":"G D\u2019Haens","year":"2001","unstructured":"D\u2019Haens G, Swijsen C, Noman M, et al.: Etanercept in the treatment of active refractory Crohn\u2019s disease: a single-center pilot trial. Am J Gastroenterol 2001, 96: 2564\u20132568.","journal-title":"Am J Gastroenterol"},{"key":"37_CR11","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","volume":"121","author":"W Sandborn","year":"2001","unstructured":"Sandborn W, Hanauer S, Katz S, et al.: Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121: 1088\u20131094.","journal-title":"Gastroenterology"},{"key":"37_CR12","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","volume":"124","author":"J Brande Van den","year":"2003","unstructured":"Van den Brande J, Braat H, van den Brink G, et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn\u2019s disease. Gastroenterology 2003, 124: 1774\u20131785.","journal-title":"Gastroenterology"},{"key":"37_CR13","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1053\/gast.2001.24042","volume":"121","author":"W Sandborn","year":"2001","unstructured":"Sandborn W, Feagan B, Hanauer S, et al.: An engineered antibody to TNF (CDP 571) for active Crohn\u2019s disease: a randomized, double-blind, placebo controlled trial. Gastroenterology 2001, 121: 1330\u20131338.","journal-title":"Gastroenterology"},{"key":"37_CR14","first-page":"A665","volume":"118","author":"B Feagan","year":"2000","unstructured":"Feagan B, Sandborn W, Baker J, et al.: A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn\u2019s disease. Gastroenterology 2000, 118: A665.","journal-title":"Gastroenterology"},{"key":"37_CR15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/gast.2002.30770","volume":"122","author":"D Hommes","year":"2002","unstructured":"Hommes D, van den Blink B, Plasse T, et al.: Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn\u2019s disease. Gastroenterology 2002, 122: 7\u201314.","journal-title":"Gastroenterology"},{"key":"37_CR16","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1046\/j.1365-2036.2002.01273.x","volume":"16","author":"J Sabate","year":"2002","unstructured":"Sabate J, Villarejo J, Lemann M, et al.: An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn\u2019s disease. Aliment Pharmacol Ther 2002, 16: 1117\u20131124.","journal-title":"Aliment Pharmacol Ther"},{"key":"37_CR17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00004836-200208000-00006","volume":"35","author":"S Kane","year":"2002","unstructured":"Kane S, Stone L, Ehrenpreis E: Thalidomide as \u201csalvage\u201d therapy for patients with delayed hypersensitivity response to infliximab: a case series. J Clin Gastroenterol 2002, 35: 149\u2013150.","journal-title":"J Clin Gastroenterol"},{"key":"37_CR18","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0016-5085(99)70277-5","volume":"117","author":"E Vasiliauskas","year":"1999","unstructured":"Vasiliauskas E, Kam L, Abreu-Martin M, et al.: An openlabel pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn\u2019s disease. Gastroenterology 1999, 117: 1278\u20131287.","journal-title":"Gastroenterology"},{"key":"37_CR19","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0016-5085(99)70276-3","volume":"117","author":"E Ehrenpreis","year":"1999","unstructured":"Ehrenpreis E, Kane S, Cohen L, et al.: Thalidomide therapy for patients with refractory Crohn\u2019s disease: an open-label trial. Gastroenterology 1999, 117: 1271\u20131277.","journal-title":"Gastroenterology"},{"key":"37_CR20","doi-asserted-by":"crossref","unstructured":"Ito H, Takazoe M, Fukuda Y, et al.: A pilot randomized trial of a human anti-interleukin 6 receptor monoclonal antibody in active Crohn\u2019s disase. Gastroenterology 2004, In press.","DOI":"10.1053\/j.gastro.2004.01.012"},{"key":"37_CR21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00054725-199911000-00001","volume":"5","author":"P Lowry","year":"1999","unstructured":"Lowry P, Weaver A, Tremaine W, Sandborn W: Combination therapy with tacrolimus and azathioprine and\/ or 6-mercaptopurine for treatment refractory Crohn\u2019s disease perianal fistulae. Inflamm Bowel Dis 1999, 5: 239\u2013245.","journal-title":"Inflamm Bowel Dis"},{"key":"37_CR22","first-page":"876","volume":"92","author":"W Sandborn","year":"1997","unstructured":"Sandborn W: Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated small bowel and fistulizing Crohn\u2019s disease. Am J Gastroenterol 1997, 92: 876\u2013879.","journal-title":"Am J Gastroenterol"},{"key":"37_CR23","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1111\/j.1572-0241.1998.539_g.x","volume":"93","author":"K Fellerman","year":"1998","unstructured":"Fellerman K, Ludwig D, Stahl M, et al.: Tacrolimus in steroid-unresponsive IBD. Am J Gastroenterol 1998, 93: 1860\u20131866.","journal-title":"Am J Gastroenterol"},{"key":"37_CR24","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0016-5085(03)00877-1","volume":"125","author":"W Sandborn","year":"2003","unstructured":"Sandborn W, Present D, Isaacs K, et al.: Tacrolimus for the treatment of fistulas in patients with Crohn\u2019s disease: a randomized, placebo-controlled trial. Gastroenterology 2003, 125: 380\u2013388.","journal-title":"Gastroenterology"},{"key":"37_CR25","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1046\/j.1365-2036.2003.01534.x","volume":"17","author":"D Baumgart","year":"2003","unstructured":"Baumgart D, Wiedenmann B, Dignass A: Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003, 17: 1273\u20131281.","journal-title":"Aliment Pharmacol Ther"},{"key":"37_CR26","first-page":"3323","volume":"96","author":"J Lewis","year":"2001","unstructured":"Lewis J, Lichtenstein G, Stein R, et al.: An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001, 96: 3323\u20133328.","journal-title":"Am J Gastroenterol"},{"key":"37_CR27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","volume":"348","author":"G Ghosh","year":"2003","unstructured":"Ghosh G, Goldin E, Gordon F, et al.: Natalizumab for active Crohn\u2019s disease. N Engl J Med 2003, 348: 24\u201332.","journal-title":"N Engl J Med"},{"key":"37_CR28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2036.2002.01205.x","volume":"16","author":"F Gordon","year":"2002","unstructured":"Gordon F, Hamilton M, Donoghue S, et al.: A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002, 16: 699\u2013705.","journal-title":"Aliment Pharmacol Ther"},{"key":"37_CR29","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(02)11437-1","volume":"460","author":"B Dieckgraefe","year":"2002","unstructured":"Dieckgraefe B, Korzenik J: Treatment of active Crohn\u2019s disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 2002, 460: 1478\u20131480.","journal-title":"Lancet"},{"key":"37_CR30","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJM200006013422203","volume":"342","author":"A Slonim","year":"2000","unstructured":"Slonim A, Buccone L, Damore M, et al.: A preliminary study of growth hormone therapy for Crohn\u2019s disease. N Engl J Med 2000, 342: 1633\u20131637.","journal-title":"N Engl J Med"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-004-0037-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-004-0037-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-004-0037-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:57:00Z","timestamp":1559422620000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-004-0037-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["37"],"URL":"https:\/\/doi.org\/10.1007\/s11938-004-0037-x","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}